LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society.
An international randomized trial in Langerhans cell histiocytosis (LCH) has been initiated by the Histiocyte Society. This report reviews the rationale, design, and progress of LCH-I, which compares etoposide (VP-16) and vinblastine in the treatment of disseminated LCH. Data on the risk of etoposide-associated (therapy-induced) malignancy, in the setting of histiocytosis, are reviewed. The available evidence leads to the recommendation that the study of etoposide in LCH should be continued.
Ladisch
S
S
Center for Cancer and Transplantation Biology, Children's Research Institute, Washington, DC 20010-2970.
Gadner
H
H
Aricò
M
M
Broadbent
V
V
Grois
N
N
Jacobson
A
A
Komp
D
D
Nicholson
H S
HS
D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy*; D006801:Humans; D007938:Leukemia / Q000139:chemically induced; D008775:Methylprednisolone / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage / Q000627:therapeutic use*
D014747:Vinblastine; D005047:Etoposide; D008775:Methylprednisolone